GenMark Diagnostics (GNMK) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq hit record highs as Treasury yields stall, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
GenMark Commences Public Offering of Common Stock
May 6, 2020 4:02 PM EDTCARLSBAD, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by GenMark. GenMark intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the... More



